A detailed history of Parallel Advisors, LLC transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 337 shares of TERN stock, worth $1,914. This represents 0.0% of its overall portfolio holdings.

Number of Shares
337
Previous 337 -0.0%
Holding current value
$1,914
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$4.54 - $8.2 $572 - $1,033
126 Added 59.72%
337 $2,000
Q1 2024

May 06, 2024

BUY
$4.86 - $8.19 $471 - $794
97 Added 85.09%
211 $1,000
Q4 2023

Feb 09, 2024

BUY
$3.37 - $6.86 $384 - $782
114 New
114 $0
Q3 2023

May 20, 2024

SELL
$4.7 - $8.55 $756 - $1,376
-161 Closed
0 $0
Q3 2023

Nov 13, 2023

SELL
$4.7 - $8.55 $756 - $1,376
-161 Closed
0 $0
Q1 2023

May 20, 2024

SELL
$7.91 - $12.0 $395 - $600
-50 Reduced 23.7%
161 $1,000
Q1 2023

Apr 25, 2023

BUY
$7.91 - $12.0 $1,273 - $1,932
161 New
161 $1,000

Others Institutions Holding TERN

About Terns Pharmaceuticals, Inc.


  • Ticker TERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,613,800
  • Market Cap $214M
  • Description
  • Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...
More about TERN
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.